[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"Ukko Inc\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":47},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,1,0,[8],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":19,"enrollmentInfo":20,"targetDuration":4,"studyType":23,"phases":24,"briefSummary":27,"conditions":28,"keywords":31,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":35,"lastUpdatePostDateStruct":36,"startDateStruct":39,"completionDateStruct":41,"leadSponsor":43,"locationsCount":46},"100619791","phase-1-ukk-0018-as-an-immunotherapeutic-for-treatment-of-peanut-allergies-100619791",false,"NCT07349212","UKK-0018 as an Immunotherapeutic for Treatment of Peanut Allergies","A First-in-Human, Ascending Dose, Open-label, Multicenter Study to Evaluate the Safety, Tolerability and Preliminary Efficacy of UKK-0018 in Peanut Allergic Individuals","UKK-0018","Inclusion Criteria:\n\n* Adults 18-55 years old\n* documented history of physician-diagnosed peanut allergy\n* positive skin prick test (SPT)\n* screening DBPCFC peanut protein\n* contraception use should be consistent with local regulations\n* capable of providing signed written informed consent\n\nExclusion Criteria:\n\n* asthma based on NHLBI\n* uncontrolled cardiovascular disease\n* chronic disease history\n* exacerbation of dermatological conditions\n* life threatening episodes of anaphylaxis\n* active infections\n* poor physical or blood chemistry\n* immunodeficiency, bleeding disorders, malignancies\n* hypersensitivities to epinephrine, inactive ingredients in therapy\n* pregnant or breast feeding","ALL","18 Years","55 Years",{"count":21,"type":22},40,"ESTIMATED","INTERVENTIONAL",[25,26],"PHASE1","PHASE2","This study will test a new investigational treatment called UKK-0018. UKK-0018 as an immunotherapeutic for the treatment of peanut allergies. The treatment is given by injection and is designed to train the immune system to tolerate peanut exposure over time.",[29,30],"Peanut-Induced Anaphylaxis","Peanut Allergy",[32,33],"peanut","peanut allergy","RECRUITING","2026-06-22",{"date":37,"type":38},"2026-06-25","ACTUAL",{"date":40,"type":38},"2026-02-18",{"date":42,"type":22},"2027-11-01",{"name":44,"class":45},"Ukko Inc","INDUSTRY",5,""]